[go: up one dir, main page]

WO2017055924A3 - Thiol and disulfide-containing agents for increasing meibomian gland lipid secretion - Google Patents

Thiol and disulfide-containing agents for increasing meibomian gland lipid secretion Download PDF

Info

Publication number
WO2017055924A3
WO2017055924A3 PCT/IB2016/001510 IB2016001510W WO2017055924A3 WO 2017055924 A3 WO2017055924 A3 WO 2017055924A3 IB 2016001510 W IB2016001510 W IB 2016001510W WO 2017055924 A3 WO2017055924 A3 WO 2017055924A3
Authority
WO
WIPO (PCT)
Prior art keywords
thiol
disulfide
meibomian gland
containing agents
lipid secretion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2016/001510
Other languages
French (fr)
Other versions
WO2017055924A2 (en
Inventor
Shimon Amselem
Yair Alster
Doron Friedman
Omer Rafaeli
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mg Therapeutics Ltd
Original Assignee
Mg Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mg Therapeutics Ltd filed Critical Mg Therapeutics Ltd
Priority to CN201680069405.8A priority Critical patent/CN108472312A/en
Priority to ES16850455T priority patent/ES3007759T3/en
Priority to KR1020187011382A priority patent/KR20180090251A/en
Priority to AU2016332966A priority patent/AU2016332966A1/en
Priority to JP2018535266A priority patent/JP2018533622A/en
Priority to CN202110338196.5A priority patent/CN113144203B/en
Priority to CA3000088A priority patent/CA3000088A1/en
Priority to EP16850455.3A priority patent/EP3313413B1/en
Publication of WO2017055924A2 publication Critical patent/WO2017055924A2/en
Publication of WO2017055924A3 publication Critical patent/WO2017055924A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Described herein are compositions and methods for the increasing the quantity of lipids secreted from meibomian glands. Such compositions and methods are useful for the treatment of meibomian gland dysfunction and disorders resulting therefrom.
PCT/IB2016/001510 2015-09-28 2016-09-28 Thiol and disulfide-containing agents for increasing meibomian gland lipid secretion Ceased WO2017055924A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
CN201680069405.8A CN108472312A (en) 2015-09-28 2016-09-28 Thiol- and disulfide-containing agents for increasing meibomian gland lipid secretion
ES16850455T ES3007759T3 (en) 2015-09-28 2016-09-28 Thiol and disulfide-containing agents for increasing meibomian gland lipid secretion
KR1020187011382A KR20180090251A (en) 2015-09-28 2016-09-28 Thiol and disulfide-containing medicines to increase myxomic lipid secretion
AU2016332966A AU2016332966A1 (en) 2015-09-28 2016-09-28 Thiol and disulfide-containing agents for increasing meibomian gland lipid secretion
JP2018535266A JP2018533622A (en) 2015-09-28 2016-09-28 Thiol and disulfide containing agents for increasing lipid secretion in the meibomian gland
CN202110338196.5A CN113144203B (en) 2015-09-28 2016-09-28 Thiol- and disulfide-containing agents for increasing lipid secretion from the meibomian glands
CA3000088A CA3000088A1 (en) 2015-09-28 2016-09-28 Thiol and disulfide-containing agents for increasing meibomian gland lipid secretion
EP16850455.3A EP3313413B1 (en) 2015-09-28 2016-09-28 Thiol and disulfide-containing agents for increasing meibomian gland lipid secretion

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562233941P 2015-09-28 2015-09-28
US201562233906P 2015-09-28 2015-09-28
US62/233,941 2015-09-28
US62/233,906 2015-09-28

Publications (2)

Publication Number Publication Date
WO2017055924A2 WO2017055924A2 (en) 2017-04-06
WO2017055924A3 true WO2017055924A3 (en) 2017-07-06

Family

ID=58408743

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2016/001510 Ceased WO2017055924A2 (en) 2015-09-28 2016-09-28 Thiol and disulfide-containing agents for increasing meibomian gland lipid secretion

Country Status (9)

Country Link
US (3) US10688122B2 (en)
EP (1) EP3313413B1 (en)
JP (2) JP2018533622A (en)
KR (1) KR20180090251A (en)
CN (2) CN108472312A (en)
AU (1) AU2016332966A1 (en)
CA (1) CA3000088A1 (en)
ES (1) ES3007759T3 (en)
WO (1) WO2017055924A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019175290A1 (en) 2018-03-13 2019-09-19 Beckley Canopy Therapeutics Limited Cannabis or cannabis derived compositions for promoting cessation of chemical dependence

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016022066A1 (en) 2014-08-04 2016-02-11 Jerry Tan Eye Surgery Pte Ltd Pharmaceutical compositions for demodex related blepharitis and eyelid crusting
US9463201B2 (en) 2014-10-19 2016-10-11 M.G. Therapeutics Ltd Compositions and methods for the treatment of meibomian gland dysfunction
KR20180090251A (en) * 2015-09-28 2018-08-10 아주라 오프탈믹스 엘티디 Thiol and disulfide-containing medicines to increase myxomic lipid secretion
EP3442519A4 (en) 2016-04-14 2019-12-04 Azura Opthalmics Ltd. SELENIUM DISULFIDE COMPOSITIONS FOR USE IN THE TREATMENT OF MEIBOMIUS GLAND DYSFUNCTION
US11484516B2 (en) 2017-03-29 2022-11-01 Azura Ophthalmics Ltd. Agents for increasing meibomian gland lipid secretion
KR20250065422A (en) 2017-12-15 2025-05-12 타르서스 파마수티칼스, 아이엔씨. Isoxazoline parasiticide formulations and methods for treating blepharitis
WO2020092402A1 (en) * 2018-10-30 2020-05-07 Harrow Health, Inc. Pharmaceutical compositions of tiopronin and methods for preparing thereof
US12239644B2 (en) * 2018-11-02 2025-03-04 Kyungpook National University Industry-Academic Cooperation Foundation Composition for prevention or treatment of macular degeneration
JP7723603B2 (en) * 2019-04-12 2025-08-14 アズーラ オフサルミックス エルティーディー． Compositions and methods for treating contact lens discomfort
EP4054703A4 (en) * 2019-11-04 2023-12-13 Azura Ophthalmics Ltd MEASURED DOSE FOR DISORDERS IN OR AROUND THE EYE
AU2020418052A1 (en) * 2020-01-02 2022-07-21 Azura Ophthalmics Ltd. Manufacturing of selenium disulfide compositions
CN115279458A (en) 2020-01-10 2022-11-01 阿祖拉眼科有限公司 Compositions and sensitivity profiles
CN116635032A (en) * 2020-10-21 2023-08-22 阿祖拉眼科有限公司 Compounds and methods for treating ocular disorders
US12286451B2 (en) 2020-11-23 2025-04-29 Medtech Products Inc. Borate ester complexes of α-hydroxy carboxylic acids and their conjugate base buffers
CA3199736A1 (en) 2020-11-23 2022-05-27 Sight Sciences, Inc. Formulations and methods for treating conditions of the eye
CN112569179B (en) * 2020-12-25 2022-12-27 上海交通大学医学院附属第九人民医院 Injectable hydrogel system and preparation method thereof
WO2023215244A1 (en) * 2022-05-02 2023-11-09 Georgetown University Use of n-acetylcysteine to treat lipid disorders and related organ dysfunctions

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090238810A1 (en) * 2006-11-30 2009-09-24 Menicon Co., Ltd. Ophthalmic composition
US20110059925A1 (en) * 2008-03-26 2011-03-10 Eric Donnenfeld Methods for improving lid margin and tear film function and treatment of lid margin disease using tetracycline family antibiotics
US20110104206A1 (en) * 2009-10-30 2011-05-05 Intratus, Inc. Methods and compositions for sustained delivery of drugs
US20110124725A1 (en) * 2004-03-12 2011-05-26 Melbj Holdings, Llc Treatment for Meibomian Gland Dysfunction or Obstruction
US8420699B1 (en) * 2002-06-19 2013-04-16 Irvine L. Dubow Composition and methods of treatment using deionized and ozonated solution
US20150265565A1 (en) * 2014-06-04 2015-09-24 Tersus Pharmaceuticals, LLC METHODS OF TREATING CHRONIC DRY EYE DISEASE USING C16:1n7-PALMITOLEATE AND DERIVATIVES THEREOF
WO2015169728A1 (en) * 2014-05-07 2015-11-12 Croma-Pharma Gesellschaft M.B.H. Aqueous ophthalmic solution and method for treating dry eye syndrome
US20170087179A1 (en) * 2015-09-28 2017-03-30 M.G. Therapeutics, Ltd. Thiol and Disulfide-Containing Agents for Increasing Meibomian Gland Lipid Secretion

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3236730A (en) 1962-01-04 1966-02-22 Miles Lab Blepharitis composition comprising antiseptic, quaternary ammonium compound, keratolytic agent and a chelating compound
US5602130A (en) 1987-03-20 1997-02-11 Allergan Disubstituted acetylenes bearing heteroaromatic and heterobicyclic groups having retinoid like activity
JP2891883B2 (en) * 1993-11-05 1999-05-17 学校法人近畿大学 Anti-cataract pharmaceutical composition
WO1997020578A1 (en) * 1995-12-04 1997-06-12 University Of Miami Non-preserved topical corticosteroid for treatment of dry eye, filamentary keratitis, and delayed tear clearance
US5965606A (en) 1995-12-29 1999-10-12 Allergan Sales, Inc. Methods of treatment with compounds having RAR.sub.α receptor specific or selective activity
EP0930072A1 (en) 1998-01-13 1999-07-21 Kartar Dr. Lalvani Vitamin and mineral containing compositions for the treatment of dry eye
US6348508B1 (en) 2000-04-04 2002-02-19 Bausch & Lomb Incorporated Method for treating dry eye
US8512718B2 (en) 2000-07-03 2013-08-20 Foamix Ltd. Pharmaceutical composition for topical application
DK1441734T3 (en) 2001-10-26 2007-06-11 Angeletti P Ist Richerche Bio Dihydroxypyrimidine carboxamide inhibitors and HIV integrase
FR2833268B1 (en) 2001-12-12 2005-07-08 Fabre Pierre Dermo Cosmetique NOVEL ASSOCIATION CONTAINING POLOXAMER AND CHONDROID SULFURIC ACID AND / OR GLYCOPROTEIN AND USE THEREOF
KR100564386B1 (en) 2002-05-13 2006-03-27 주식회사 마이코플러스 4-hydroxy-5-methoxy-4- [2-methyl-3- (3-methyl-2-butenyl) -2-oxalanyl] -1-oxaspiro [2,5] octane-6- Pharmaceutical composition for treating seborrhea containing ions
BR0312817A (en) 2002-07-23 2005-04-19 Novartis Ag Ophthalmic ointment composition comprising a drug, an ointment base and a solubilizing / dispersing agent
US7288259B2 (en) 2002-08-19 2007-10-30 Ira Sanders Treatment of holocrine gland dysfunction with clostridia neurotoxins
US20040171561A1 (en) 2002-09-03 2004-09-02 Popp Karl F. Topical formulations for treatment of rosacea
WO2004028536A1 (en) 2002-09-30 2004-04-08 Babizhayev Mark A Method for topical treatment of eye disease and composition and device for said treatment
US20060188471A1 (en) 2002-10-31 2006-08-24 Podolsky Daniel K Methods of treating epithelial lesions
GB0225795D0 (en) 2002-11-05 2002-12-11 Guillon Michael Wipes
US20070269537A1 (en) 2003-02-10 2007-11-22 Bioderm Research Skin Condition Improvement Including Acne, Rosacea, and Topical Wounds by Artemisia Annua Extract via Iron Siderophore Trojan Horse Delivery System
GB0322448D0 (en) 2003-09-25 2003-10-29 Lamellar Therapeutics Ltd Using lamellar bodies to modify linear biological macro molecules
US20050197614A1 (en) 2004-03-04 2005-09-08 Wilson Pritchard Occlusive biomedical devices, punctum plugs, and methods of use thereof
US20050202097A1 (en) 2004-03-12 2005-09-15 Melbj Holdings, Llc, Florida Lubricant for the ocular surface
EP1621191A1 (en) 2004-07-29 2006-02-01 Werner Bollag Treatment of inflammatory diseases by RXR Antagonists
US20090214676A1 (en) 2005-04-30 2009-08-27 Tissuetech, Inc. Method for treating ocular demodex
CA2613247A1 (en) * 2005-06-22 2006-12-28 Kowa Company, Ltd. Prophylactic or therapeutic agent for corneal/conjunctival disease
US7981095B2 (en) 2005-07-18 2011-07-19 Tearscience, Inc. Methods for treating meibomian gland dysfunction employing fluid jet
US20070016256A1 (en) 2005-07-18 2007-01-18 Korb Donald R Method and apparatus for treating gland dysfunction
WO2013003594A2 (en) 2011-06-28 2013-01-03 Tearscience, Inc. Methods and systems for treating meibomian gland dysfunction using radio-frequency energy
US20070166402A1 (en) 2005-12-12 2007-07-19 Friedlaender Mitchell H Compositions, methods and kits for removing debris from an ocular area
EP2677039B8 (en) 2006-05-10 2022-10-05 DxTerity Diagnostics Incorporated Detection of nucleic acid targets using chemically reactive oligonucleotide probes
US8568790B2 (en) 2006-05-31 2013-10-29 Medihoney Pty Ltd. Medicinal compositions containing honey
WO2008027069A1 (en) 2006-08-21 2008-03-06 Tearscience, Inc. Method and apparatus for treating meibomian gland dysfunction employing fluid
US8249695B2 (en) 2006-09-29 2012-08-21 Tearscience, Inc. Meibomian gland imaging
US8090426B2 (en) 2006-10-27 2012-01-03 Felder Robin A Microelectronic biosensor plug
US20100204317A1 (en) 2006-11-03 2010-08-12 Qlt Inc. Methods of treating dermatological disorders or conditions
CN101668511A (en) * 2007-02-28 2010-03-10 阿西克斯医疗公司 methods and compositions for normalizing meibomian gland secretions
US8128968B2 (en) 2007-08-29 2012-03-06 Tissuetech, Inc. Compositions and methods for treating Demodex infestations
MX2010003364A (en) 2007-10-08 2010-07-06 Lux Biosciences Inc Ophthalmic compositions comprising calcineurin inhibitors or mtor inhibitors.
JP5552482B2 (en) 2008-04-30 2014-07-16 キュー エル ティー インク． Composite lacrimal insert and related methods
JP5661035B2 (en) 2008-07-10 2015-01-28 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ Cyclosporine derivatives for the treatment of eye and skin diseases and conditions
WO2010033800A2 (en) 2008-09-19 2010-03-25 Alacrity Biosciences, Inc. Tetracycline stabilizing formulations
PT2424374T (en) 2009-05-01 2018-04-23 Advanced Vision Res Inc Cleanser compositions and methods for using the same
CN101612161A (en) 2009-08-07 2009-12-30 魏谠全 A kind of eye medicine combination and preparation thereof
CA2780453A1 (en) 2009-12-02 2011-06-09 Bridge Pharma, Inc. Treating xerophthalmia with compounds increasing meibomian gland secretion
US20120093876A1 (en) 2010-10-13 2012-04-19 Aciex, Inc. Ophthalmic Formulations, Methods Of Manufacture And Methods of Normalizing Meibomian Gland Secretions
WO2012063237A2 (en) 2010-11-08 2012-05-18 Healor Ltd. Buffered ophthalmic compositions and methods of use thereof
US20130281390A1 (en) 2010-12-29 2013-10-24 Kurt E. Brubaker Method for treating dry eye
WO2012092378A1 (en) 2010-12-29 2012-07-05 Inspire Pharmaceuticals, Inc. Method for treating blepharitis
WO2012092320A2 (en) 2010-12-29 2012-07-05 Nichamin Louis D Eye treatment
US9119772B2 (en) 2011-01-26 2015-09-01 Allergan, Inc. Androgen composition for treating an opthalmic condition
BR112013029592A2 (en) 2011-05-20 2019-09-24 Univ Keio "metalloprotein and process for its production, and prophylactic or therapeutic people for corneal and conjunctival diseases comprising said metalloprotein"
JP2014518275A (en) * 2011-06-29 2014-07-28 インサイト・ビジョン・インコーポレイテッド Method for treating recurrent meibomian gland disorders and method for reducing the frequency of relapse thereby
ITFI20120044A1 (en) 2012-03-01 2013-09-02 Biodue Spa FORMULATION FOR OPHTHALMIC USE INCLUDING JOJOBA OIL.
WO2013156493A1 (en) * 2012-04-16 2013-10-24 Lipotec S.A. Compounds for the treatment and/or care of the skin and/or mucous membranes and their use in cosmetic or pharmaceutical compositions
WO2014078956A1 (en) * 2012-11-20 2014-05-30 Revive Therapeutics Inc. The use of bucillamine in the treatment of gout
US9211397B2 (en) * 2012-12-19 2015-12-15 Senju Usa, Inc. Patch for treatment of eyelid disease containing clobetasol
WO2015017316A2 (en) * 2013-08-01 2015-02-05 Abbott Nicholas L Methods and compositions for modifying mucous membranes
HUE14755117T2 (en) 2013-08-14 2018-12-28 Kalvista Pharmaceuticals Ltd Inhibitors of plasma kallikrein
US9463201B2 (en) * 2014-10-19 2016-10-11 M.G. Therapeutics Ltd Compositions and methods for the treatment of meibomian gland dysfunction
EP3442519A4 (en) * 2016-04-14 2019-12-04 Azura Opthalmics Ltd. SELENIUM DISULFIDE COMPOSITIONS FOR USE IN THE TREATMENT OF MEIBOMIUS GLAND DYSFUNCTION
US20200179305A1 (en) 2016-04-19 2020-06-11 Azura Ophthalmics Ltd. Compositions for the Treatment of Hyperkeratosis Disorders

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8420699B1 (en) * 2002-06-19 2013-04-16 Irvine L. Dubow Composition and methods of treatment using deionized and ozonated solution
US20110124725A1 (en) * 2004-03-12 2011-05-26 Melbj Holdings, Llc Treatment for Meibomian Gland Dysfunction or Obstruction
US20090238810A1 (en) * 2006-11-30 2009-09-24 Menicon Co., Ltd. Ophthalmic composition
US20110059925A1 (en) * 2008-03-26 2011-03-10 Eric Donnenfeld Methods for improving lid margin and tear film function and treatment of lid margin disease using tetracycline family antibiotics
US20110104206A1 (en) * 2009-10-30 2011-05-05 Intratus, Inc. Methods and compositions for sustained delivery of drugs
WO2015169728A1 (en) * 2014-05-07 2015-11-12 Croma-Pharma Gesellschaft M.B.H. Aqueous ophthalmic solution and method for treating dry eye syndrome
US20150265565A1 (en) * 2014-06-04 2015-09-24 Tersus Pharmaceuticals, LLC METHODS OF TREATING CHRONIC DRY EYE DISEASE USING C16:1n7-PALMITOLEATE AND DERIVATIVES THEREOF
US20170087179A1 (en) * 2015-09-28 2017-03-30 M.G. Therapeutics, Ltd. Thiol and Disulfide-Containing Agents for Increasing Meibomian Gland Lipid Secretion

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BUTOVICH ET AL.: "Human tear film and meibum.Very long chain wax esters and (O-acyl)-omega- hydroxy fatty acids of meibum", JOURNAL OF LIPID RESEARCH, vol. 50, 2009, pages 2471, XP055157215 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019175290A1 (en) 2018-03-13 2019-09-19 Beckley Canopy Therapeutics Limited Cannabis or cannabis derived compositions for promoting cessation of chemical dependence

Also Published As

Publication number Publication date
ES3007759T3 (en) 2025-03-20
CN108472312A (en) 2018-08-31
CN113144203B (en) 2025-01-28
US10688122B2 (en) 2020-06-23
CN113144203A (en) 2021-07-23
EP3313413A2 (en) 2018-05-02
EP3313413B1 (en) 2024-12-04
CA3000088A1 (en) 2017-04-06
KR20180090251A (en) 2018-08-10
EP3313413A4 (en) 2018-07-11
EP3313413C0 (en) 2024-12-04
JP7138694B2 (en) 2022-09-16
JP2021063083A (en) 2021-04-22
AU2016332966A1 (en) 2018-04-26
JP2018533622A (en) 2018-11-15
US20170087179A1 (en) 2017-03-30
US20220226367A1 (en) 2022-07-21
WO2017055924A2 (en) 2017-04-06
US20200179440A1 (en) 2020-06-11

Similar Documents

Publication Publication Date Title
WO2017055924A3 (en) Thiol and disulfide-containing agents for increasing meibomian gland lipid secretion
MX2019011697A (en) Agents for increasing meibomian gland lipid secretion.
CL2018003582A1 (en) Compositions to modulate the expression of c9orf72 (divisional application 201702567)
ZA201902968B (en) Method for increasing the secretion levels of interleukin 2 and proteins derived from it
IL273943A (en) Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
MY197631A (en) Formulations of (r)-2-amino-3-phenylpropyl carbamate
WO2020123773A3 (en) Anellosomes for delivering secreted therapeutic modalities
IL255109A0 (en) Novel dihydropyridoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders
WO2020123795A3 (en) Anellosomes for delivering protein replacement therapeutic modalities
EP3634426A4 (en) Compositions for the treatment of fibrosis
EP3720421A4 (en) Compositions and methods for the treatment of metabolic conditions
EP3651747A4 (en) Compositions and methods for the treatment of eye disorders
IL286677A (en) Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
EP3348273B8 (en) Compositions based on xyloglucan and proteins for the treatment of intestinal disorders
GB201610056D0 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders and osteoarthritis
IL286688A (en) Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
GB201911868D0 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
GB201610055D0 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders and osteoarthritis
IL286685A (en) Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
GB201702603D0 (en) Novel compositions and pharmaceutical compositions thereof for the treatment of inflammatory disorders
EP3554494A4 (en) Compositions and methods for the treatment of inflammation
HK40018438A (en) Agents for increasing meibomian gland lipid secretion
NZ723269A (en) Sulfonamide and sulfinamide prodrugs of fumarates and their use in treating various diseases
HK40061263A (en) Compositions and methods for the treatment of liver disorders
HK40015857A (en) New compositions for the treatment of articular disorders

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16850455

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2016850455

Country of ref document: EP

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16850455

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2018535266

Country of ref document: JP

ENP Entry into the national phase

Ref document number: 3000088

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 20187011382

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2016332966

Country of ref document: AU

Date of ref document: 20160928

Kind code of ref document: A